12 August 2023 : Clinical Research
Transgastric Jejunostomy (PEG-J) for Continuous Infusion of Levodopa-Carbidopa Intestinal Gel: An Approach for Parkinson's Disease Treatment
Yusuke Nomoto1ABCDEF*, Makoto Furihata1ABCDEF, Haruka Hagiwara1F, Hirotaka Ishino1B, Shintaro Yano1D, Hiroki Okawa1B, Yoichi Nakatsu1B, Kumiko Noda1B, Shinjiro Nishi1F, Shingo Ogiwara1AB, Tsuneo Kitamura1D, Taro Osada1AGDOI: 10.12659/MSM.941285
Med Sci Monit 2023; 29:e941285
Table 5 Therapeutic outcomes of LCIG on neurological aspects.
Therapeutic outcomes | Before LCIG | After LCIG |
---|---|---|
MDS-UPDRS | 26.44±3.3 (range: 4–59) | 17.6±2.1 (range: 0–59) |
ON-OFF ratio* | 24: 18 | 42: 0 |
Levodopa equivalent daily dose at discharge | 1223.7±336.6 (range: 656–2000) mg | |
Additional therapy at discharge | ||
Rotigotine patch (n=27) | 11±5.49 (range 4.5–22.5) mg | |
Levodopa-carbidopa combination tablet (n=1) | 300 mg | |
Pramipexole (n=1) | 0.375 mg | |
Ropinirole (n=1) | 32 mg | |
LCIG – levodopa-carbidopa intestinal gel; MDS-UPDRS – Movement Disorder Society Unified Parkinson’s Disease Rating Scale. * One patient could not be evaluated. Data are presented as mean±standard deviation. |